Nanohsa-Rotop (Human Serum Albumin)

Human Serum Albumin, the active ingredient in Nanohsa-Rotop, is a plasma protein presented as a sterile injectable solution for intravenous and subcutaneous use. It is employed to restore plasma oncotic pressure and expand intravascular volume in patients with hypovolemia, shock, severe burns, or hypoalbuminemia, particularly in critical care settings.

GNH USA supplies Nanohsa-Rotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to EU GMP standards and provides cold‑chain logistics for safe delivery to healthcare facilities.

Nanohsa‑Rotop, a human serum albumin preparation, is used in clinical situations that require plasma volume expansion.

- Hypovolemia: restores intravascular volume and improves tissue perfusion. - Shock: supports circulatory stability by increasing oncotic pressure. - Severe burns: aids fluid resuscitation and maintains plasma protein levels. - Hypoalbuminemia: replenishes deficient albumin to correct oncotic deficits.

Adverse reactions may occur with any albumin infusion.

Common Side Effects: - Fever: transient rise in body temperature following infusion. - Chills: sensation of cold or shivering during or after administration. - Hypotension: mild drop in blood pressure, especially with rapid infusion. - Injection site pain: discomfort at the site of intravenous or subcutaneous delivery.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical intervention. - Pulmonary edema: fluid accumulation in the lungs due to excessive volume expansion. - Severe hypertension: marked increase in blood pressure that may need urgent treatment.

Special considerations are required when using Nanohsa‑Rotop.

- Renal impairment: monitor fluid balance and renal function closely. - Cardiac failure: use cautiously to avoid fluid overload. - Pregnancy: safety not established; weigh potential benefits against risks. - Allergy: assess for known hypersensitivity to human albumin before administration. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be evaluated before therapy.

Major Interactions (Avoid): - Concurrent use with high‑dose diuretics in hypovolemic patients may cause severe hypotension. - Co‑administration with other volume expanders can lead to fluid overload.

Moderate Interactions (Monitor Closely): - Nephrotoxic agents: monitor renal function during combined therapy. - Anticoagulants: observe for altered bleeding risk. - Vasopressors: dose adjustments may be needed based on hemodynamic response.